Christopher Senner Insider Profile
11 Followers
Christopher Senner, Director at Quince Therapeutics, holds ― shares in Quince Therapeutics (Ticker: QNCX), holds 955.04K shares in Exelixis (Ticker: EXEL). Most recently, Christopher Senner ― shares of Quince Therapeutics on ― for an estimated value of ―.
Christopher Senner Quince Therapeutics (QNCX)Director
Quince Therapeutics (QNCX)
Director
Ranked #79,428 out of 108,921 Corporate Insiders
Profitable Transactions
3 out of 9 Profitable Transactions
Average Return
-10.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Christopher Senner holds in companies
Most Profitable Insider Trade
The most profitable trade made by Christopher Senner
Christopher Senner's Trading History
Quince Therapeutics
―
Director
―
―
Exelixis
May 19, 2026
EVP & CFO
Informative Sell
3.83M
$55.08M
List of latest transactions for each holding click on a transaction to see Christopher Senner's performance on stock
You May Also Like
Christopher Senner insider profile FAQ
What is the percentage of profitable transactions made by Christopher Senner?
The percentage of profitable transactions made by Christopher Senner is 33%.
What is the average return per transaction made by Christopher Senner?
The average return per transaction made by Christopher Senner is -10.40%.
What stocks does Christopher Senner hold?
Christopher Senner holds: QNCX, EXEL stocks.
What was Christopher Senner’s latest transaction?
Christopher Senner latest transaction was an Uninformative Buy of ―.
What was Christopher Senner's most profitable transaction?
Christopher Senner’s most profitable transaction was an Informative Sell of EXEL stock on September 14, 2017. The return on the trade was 37.70%.
What is Christopher Senner's role in Quince Therapeutics?
Christopher Senner's role in Quince Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.